CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with increased net income and adjusted EBITDA. The company reaffirmed its guidance and highlighted market opportunities for its products. Despite some uncertainties in trials and regulatory feedback, management's optimistic guidance and strategic focus on Medicare Advantage expansion are positive indicators. The Q&A section did not reveal significant negative concerns, maintaining a positive sentiment. However, lack of specific details on trial amendments and pricing strategies limits stronger optimism. Overall, the positive financial results and strategic initiatives suggest a likely stock price increase in the short term.
Key Financial Performance
Net Revenue (Q1 2026) $127.4 million, compared to $39.1 million in Q1 2025, representing a significant year-over-year increase. The increase was driven by higher sustained DefenCath demand, including sales to a large dialysis customer onboarded mid-last year, and the addition of Melinta portfolio revenue.
DefenCath Revenue (Q1 2026) $97.5 million, with a $9 million nonrecurring favorable change in estimate related to sales allowances. The increase was due to higher demand and the impact of a large dialysis customer.
Melinta Portfolio Revenue (Q1 2026) $29.9 million, contributing to the overall revenue growth due to the acquisition of Melinta in August 2025.
Operating Expenses (Q1 2026) $41.5 million, including $7.2 million in R&D, $12.5 million in selling and marketing, and $21.7 million in G&A. The increase reflects the larger combined company, higher personnel costs, and expanded commercial and IT infrastructure.
Net Income (Q1 2026) $38.6 million, or $0.48 per basic share and $0.43 per diluted share, compared to $20.6 million, or $0.32 per basic share and $0.30 per diluted share in Q1 2025. The increase was driven by higher revenue and operational performance.
Adjusted EBITDA (Q1 2026) $70 million, compared to $23.6 million in Q1 2025, reflecting strong core operating performance. This excludes acquisition-related costs, stock-based compensation, and nonrecurring revenue adjustments.
Cash and Cash Equivalents (End of Q1 2026) $178.1 million, excluding restricted cash. The increase was supported by $42.4 million in cash generated from operating activities, offset by $11.1 million used for stock buybacks.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DefenCath Utilization: DefenCath continues to exceed expectations with strong underlying utilization demand. The company raised its full-year DefenCath guidance from $150-$170 million to $175-$195 million. DefenCath is evolving into a standard of care therapy within its target population, supported by strong clinical value and increasing adoption.
REZZAYO Development: Preliminary top-line clinical results from the ReSPECT study showed REZZAYO met its primary endpoint for fungal-free survival at day 90, demonstrating non-inferiority versus the standard antifungal regimen. The results position REZZAYO as a differentiated prophylactic therapy with a meaningful commercial opportunity. FDA submission of the sNDA is planned for the second half of 2026, with a potential commercial launch in 2027.
Revenue Growth: First quarter 2026 net revenue was $127.4 million, significantly above the previous year's $39.1 million. This includes $97.5 million from DefenCath and $29.9 million from the Melinta portfolio. Full-year net revenue guidance was raised to $325-$345 million from $300-$320 million.
Operational Efficiency: Adjusted EBITDA for Q1 2026 was $70 million, up from $23.6 million in Q1 2025. The company generated $42.4 million in cash from operating activities during the quarter, reflecting strong operational execution.
Cost Management: Operating expenses for Q1 2026 were $41.5 million, reflecting investments in personnel, commercial infrastructure, and development activities. Cash OpEx guidance for the year is $145-$160 million.
Pipeline Expansion: The company is advancing late-stage opportunities, including REZZAYO for prophylaxis and DefenCath in TPN, which could significantly expand long-term revenue potential.
Commercial Readiness: CorMedix is preparing for the potential launch of REZZAYO in 2027, with plans to add 15-20 incremental headcount in commercial and medical roles in the second half of 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
DefenCath reimbursement transition: The expiration of the initial TDAPA reimbursement and the transition to the post-TDAPA add-on phase of reimbursement by CMS in the second half of 2026 could lead to variability in DefenCath sales. This poses a risk to maintaining or growing patient utilization during this transition period.
TPN study delays: The Phase III TPN study is experiencing delays due to lower-than-expected enrollment and lower cumulative infection rates, pushing the study completion timeline into 2028. This delay could impact the company's ability to bring the product to market as planned.
Increased operating expenses: The company anticipates higher operating expenses in the second half of 2026 due to the planned addition of 15 to 20 incremental headcount and other commercial readiness activities for the potential launch of REZZAYO. This could strain financial resources if revenue growth does not meet expectations.
Regulatory dependencies: The success of REZZAYO's sNDA submission and subsequent commercial launch in 2027 is dependent on regulatory approvals and collaboration with the global partner Mundipharma. Any delays or issues in this process could impact the company's strategic plans.
Market competition: The company faces competitive pressures in the antifungal and infection prevention markets, which could impact the adoption and profitability of products like DefenCath and REZZAYO.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year Financial Guidance: Net revenue guidance increased from $300 million-$320 million to $325 million-$345 million for 2026. Adjusted EBITDA guidance raised from $100 million-$125 million to $115 million-$135 million.
DefenCath Revenue Guidance: Full year DefenCath revenue guidance increased from $150 million-$170 million to $175 million-$195 million. Guidance is based on existing customer run rates and excludes potential upside from new customers or Medicare Advantage contracting.
Reimbursement Dynamics: DefenCath sales variability expected in the second half of 2026 due to the expiration of TDAPA reimbursement and transition to post-TDAPA add-on phase. Significant increase in post-TDAPA add-on amount anticipated in 2027, leading to higher net selling price per unit.
REZZAYO Commercial Launch: FDA submission of sNDA for REZZAYO planned for the second half of 2026, with potential commercial launch in 2027. Incremental spend expected in the second half of 2026 for commercial readiness, including 15-20 additional headcount.
TPN Study Timeline: Phase III TPN study completion now trending into 2028 due to slower enrollment and lower-than-expected infection rates. Steps being taken to accelerate timeline, including opening additional clinical sites and submitting a protocol amendment to FDA.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Stock Buyback Program: During the quarter, we generated cash from operating activities of $42.4 million, which was impacted by large incentive rebate payments made to customers during the first quarter. Cash flow from operating activities was partially offset by $11.1 million used in cash to repurchase shares under our stock buyback program, driving a $33.3 million increase in cash during the first quarter.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What revenue trend should be expected for DefenCath in the second quarter, and what are the updated thoughts on the guidance for DefenCath in 2027?
A:The second quarter is expected to be a '2-month quarter' due to a shelf stock adjustment in June, with revenue projected around $60 million. For 2027, management affirmed previous guidance, expecting appreciation in net selling price compared to Q3 and Q4 of the current year. Guidance does not include potential upside from Medicare Advantage or new customers.
Q:Can you provide more details on the changes in the TPN trial's exclusion/inclusion criteria and its impact on enrollment and patient profile?
A:Management did not provide specifics on the changes requested from the FDA but mentioned that the patient pool is smaller due to the complexity of TPN patients. They are seeking to amend inclusion criteria to potentially include more patients without compromising data. Enrollment timelines could shift if the amendment is approved.
Q:What strategies are being used to increase customer run rates for DefenCath?
A:Management observed an uptick in utilization from Q4 to Q1 and is focusing on outreach to Medicare Advantage to expand the patient pool. Currently, over 90% of patients are in Medicare fee-for-service, presenting a long-term opportunity in Medicare Advantage.
Q:Does the amendment to the TPN study protocol impact the statistical plan or future label?
A:Yes, the statistical plan would change if the amendment is approved. However, management does not anticipate changes to the projected label, which focuses on risk reduction of CLABSI in adult TPN patients. The label could potentially expand depending on FDA feedback.
Q:What are the assumptions and early feedback regarding REZZAYO's payer negotiations, pricing, and utilization?
A:The full data for REZZAYO has not yet been published, so discussions with KOLs and market research for pricing and penetration are pending. More details are expected later in the year.
Q:What customer or payer actions have followed the positive real-world data for DefenCath?
A:The real-world data has been positively received, with public endorsements from U.S. Renal Care, IRC, and Fresenius. This data is being used in ongoing discussions with Medicare Advantage plans.
Q:Has the priority for bringing in additional assets changed given the success of REZZAYO?
A:No, the priority remains high. Management is focused on finding complementary products for hematology/oncology clinics and bone marrow transplant centers.
Q:Will additional trials be required for the REZZAYO sNDA filing, and what clarity is expected from the pre-NDA meeting?
A:The pre-NDA meeting will confirm if the ReSPECT trial data and other supportive data are sufficient for the sNDA filing. Clarity on the potential label will come later in the process.
Q:What is the normalized run rate for DefenCath, and how does inventory impact guidance?
A:The largest customer holds about 4 weeks of stock, with others holding 2-3 weeks. The second quarter includes a shelf stock adjustment in June. Utilization is expected to remain strong, with price erosion in Q3 and Q4 due to the transition to a bundled payment system.
Q:Why was the tax rate high, and what is the normalized tax rate going forward?
A:The GAAP tax rate is about 28%, reflecting the statutory federal and state rates. While the company has significant NOLs to reduce taxable income, the GAAP rate remains at the statutory level due to minimal permanent differences.
Q:Review of Unclear Management Responses
A:Management avoided providing specifics on the changes to the TPN trial's inclusion/exclusion criteria, stating they need FDA feedback before commenting further. Additionally, they deferred detailed discussions on REZZAYO's pricing and utilization until the full data is published and conversations with KOLs are conducted.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chairman Chief
Chief Financial
Chief Officer
CorMedix Corporate
FDA
Financial Officer
Hurlburt
NDA
REZZAYO prophylaxis
ReSPECT study
SAR
Todisco Chairman
antifungal regimen
approval
balance sheet
change estimate
consensus
core
demand
efficacy
endpoint
enrollment
excludes
expiration
fee
fungal survival
line result
objective
participant
party
portfolio
priority
rebate
result REZZAYO
result ReSPECT
sNDA
spend
submission
survival day
variability
CRMD Transcript
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call reveals strong financial performance with increased net income and adjusted EBITDA. The company reaffirmed its guidance and highlighted market opportunities for its products. Despite some uncertainties in trials and regulatory feedback, management's optimistic guidance and strategic focus on Medicare Advantage expansion are positive indicators. The Q&A section did not reveal significant negative concerns, maintaining a positive sentiment. However, lack of specific details on trial amendments and pricing strategies limits stronger optimism. Overall, the positive financial results and strategic initiatives suggest a likely stock price increase in the short term.
CorMedix Inc. (CRMD) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings report shows strong revenue and EBITDA growth, a raised guidance, and a successful share repurchase program, all contributing positively. However, uncertainties in supply pricing negotiations and legislative outcomes create some risk. The Q&A highlights ongoing strategic customer and legislative efforts, which, if successful, could further enhance financial performance. Overall, the positive aspects outweigh the uncertainties, suggesting a positive sentiment and potential stock price increase.
CorMedix Inc. (CRMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
CorMedix Inc. (CRMD) Q3 2025 Earnings Call Transcript
Unknown11-12
The earnings call summary provides mixed signals. While there are positive aspects such as potential revenue growth from REZZAYO and DefenCath, and expected synergies from the Melinta acquisition, there are concerns about increased operating expenses and lack of clear financial guidance for 2026. The Q&A session reveals some uncertainties, particularly around pricing dynamics post-TDAPA and exact utilization figures for DefenCath. These mixed elements suggest a neutral sentiment, indicating the stock price may remain stable over the next two weeks.
CRMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
